ERβ overexpression may not be a direct prognostic factor in patients with NSCLC: A meta-analysis.

IF 2.3 4区 医学 Q3 BIOTECHNOLOGY & APPLIED MICROBIOLOGY
Hui Li, Haishegn Chen, Jing Shi, Qing Fan, Zhongxia Zhou, Xiufeng Tang, Yanhong Wang, Yuguo Liu
{"title":"ERβ overexpression may not be a direct prognostic factor in patients with NSCLC: A meta-analysis.","authors":"Hui Li,&nbsp;Haishegn Chen,&nbsp;Jing Shi,&nbsp;Qing Fan,&nbsp;Zhongxia Zhou,&nbsp;Xiufeng Tang,&nbsp;Yanhong Wang,&nbsp;Yuguo Liu","doi":"10.1177/03936155221105521","DOIUrl":null,"url":null,"abstract":"<p><p>Overall survival of non-small cell lung cancer (NSCLC) patients remains disappointingly low. The estrogen receptor (ER) was considered a promising therapeutic target for NSCLC. Numerous studies have linked expression of ERβ to lung cancer outcome. However, results are conflicting regarding the association of ERβ with surviving lung cancer. The aim of this meta-analysis was to evaluate the prognostic aspect of ERβ expression on survival among NSCLC patients. We performed a final analysis of prognostic value of overexpression ERβ on 3500 patients from 18 evaluable studies (from January 1, 2000 to May 1, 2021). The reference category is specified as low ERβ expression levels. Summarized hazard ratios were calculated. Our study showed that the pooled hazard ratios of ERβ overexpression for overall survival in NSCLC was 0.81 (95% confidence interval (CI): 0.64-1.02, <i>P</i> = 0.07) by univariate analysis and 1.06 (95% CI: 0.83-1.36, <i>P </i>= 0.63) by multivariate analysis. Pooled hazard ratio by univariate analysis in Asian studies was 0.73 (95%CI: 0.59-0.89, <i>P</i> = 0.002). Pooled hazard ratio by univariate analysis was 0.75 (95% CI: 0.61-0.93, <i>P</i> = 0.009) from seven studies reported for nuclear ERβ. No significant results were found in subgroups by multivariate analysis. No significant results were found in studies outside Asia or in studies reported for cytoplasmic ERβ. Our results suggested that expression of ERβ might not be a direct prognostic factor for NSCLC patients. More detailed prospective studies are needed to identify direct prognostic factors in these patients.</p>","PeriodicalId":50334,"journal":{"name":"International Journal of Biological Markers","volume":null,"pages":null},"PeriodicalIF":2.3000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Biological Markers","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/03936155221105521","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/6/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Overall survival of non-small cell lung cancer (NSCLC) patients remains disappointingly low. The estrogen receptor (ER) was considered a promising therapeutic target for NSCLC. Numerous studies have linked expression of ERβ to lung cancer outcome. However, results are conflicting regarding the association of ERβ with surviving lung cancer. The aim of this meta-analysis was to evaluate the prognostic aspect of ERβ expression on survival among NSCLC patients. We performed a final analysis of prognostic value of overexpression ERβ on 3500 patients from 18 evaluable studies (from January 1, 2000 to May 1, 2021). The reference category is specified as low ERβ expression levels. Summarized hazard ratios were calculated. Our study showed that the pooled hazard ratios of ERβ overexpression for overall survival in NSCLC was 0.81 (95% confidence interval (CI): 0.64-1.02, P = 0.07) by univariate analysis and 1.06 (95% CI: 0.83-1.36, P = 0.63) by multivariate analysis. Pooled hazard ratio by univariate analysis in Asian studies was 0.73 (95%CI: 0.59-0.89, P = 0.002). Pooled hazard ratio by univariate analysis was 0.75 (95% CI: 0.61-0.93, P = 0.009) from seven studies reported for nuclear ERβ. No significant results were found in subgroups by multivariate analysis. No significant results were found in studies outside Asia or in studies reported for cytoplasmic ERβ. Our results suggested that expression of ERβ might not be a direct prognostic factor for NSCLC patients. More detailed prospective studies are needed to identify direct prognostic factors in these patients.

ERβ过表达可能不是NSCLC患者的直接预后因素:一项荟萃分析。
非小细胞肺癌(NSCLC)患者的总生存率仍然低得令人失望。雌激素受体(ER)被认为是治疗非小细胞肺癌的一个有前景的靶点。许多研究已经将ERβ的表达与肺癌的预后联系起来。然而,关于ERβ与肺癌存活率的关系,结果是相互矛盾的。本荟萃分析的目的是评估ERβ表达对NSCLC患者生存的预后方面。我们对来自18项可评估研究(2000年1月1日至2021年5月1日)的3500名患者进行了ERβ过表达的预后价值的最终分析。参考类别指定为低ERβ表达水平。计算汇总风险比。我们的研究显示,单因素分析ERβ过表达对NSCLC总生存率的合并风险比为0.81(95%可信区间(CI): 0.64-1.02, P = 0.07),多因素分析的合并风险比为1.06 (95% CI: 0.83-1.36, P = 0.63)。亚洲研究中单因素分析的合并风险比为0.73 (95%CI: 0.59-0.89, P = 0.002)。单因素分析的合并风险比为0.75 (95% CI: 0.61-0.93, P = 0.009)。多变量分析未发现亚组有显著性结果。在亚洲以外的研究或细胞质ERβ研究中未发现显著结果。我们的结果表明,ERβ的表达可能不是非小细胞肺癌患者的直接预后因素。需要更详细的前瞻性研究来确定这些患者的直接预后因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
International Journal of Biological Markers
International Journal of Biological Markers 医学-生物工程与应用微生物
CiteScore
4.10
自引率
0.00%
发文量
43
期刊介绍: IJBM is an international, online only, peer-reviewed Journal, which publishes original research and critical reviews primarily focused on cancer biomarkers. IJBM targets advanced topics regarding the application of biomarkers in oncology and is dedicated to solid tumors in adult subjects. The clinical scenarios of interests are screening and early diagnosis of cancer, prognostic assessment, prediction of the response to and monitoring of treatment.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信